Castate resistant metastatic prostate cancer (mRPC) withvisceral disease (tumors involving the internal organs of the body, specifically those within the chest (as the heart or lungs) or abdomen (as the liver, pancreas or intestines) is a negative prognostic factor. In many cases clinical trials of new investigational drugs rule out men with visceral disease from [...]
Prostate cancer is not just one disease; in reality there are several different types of prostate cancer, which will look different under a microscope and behave differently in your body. In addition to the more common types of prostate cancer there are also several kinds of rare cancers that can develop in the prostate. Prostate [...]
In prior posts I have strongly recommended that, if possible, it is in your best interest not to go into the hospital in the month of July. The month of July is the traditional beginning of a new rotation for the new hospital Residents, or there are an overwhelming number of newly minted doctors with [...]
It was announced today that after observing significant benefits in overall survival (OS) and radiographic progression free survival (PFS) ,the two co-primary endpoints of the the Xtandi pre-chemotherapy trial, the Independent Data Monitoring Committee (IDMC) for The Phase 3 PREVAIL trial of enzalutamide in metastatic prostate cancer recommends that "the study be stopped and patients [...]
Last Thursday’s New York Times had an article about Dr. Perry Hudson, in 1950s a medical researcher at Columbia University. The article was about his research on skid row in New York City where he offered alcoholics in lower Manhattan an offer: If they agreed to surgical biopsies of their prostates, they would get a [...]